From Wikipedia, the free encyclopedia
Jump to: navigation, search
Legal status
Legal status
  • US: Not FDA approved; unscheduled
CAS Number
PubChem CID
Chemical and physical data
Formula C14H18N2O2
Molar mass 246.304 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Sunifiram (DM-235) is a piperazine derived research chemical which has anti-amnesiac effects in animal studies with significantly higher potency than piracetam.[1] Sunifiram is a molecular simplification of unifiram.[2] Based on in vitro and animal studies, it appears that sunifiram acts via AMPA-receptor activation.[3]

As of 2016, sunifiram had not been subjected to toxicology testing, nor to any human clinical trials, and is not approved for use anywhere in the world.[1]


  1. ^ a b Gualtieri F (2016). "Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings". Journal of Enzyme Inhibition and Medicinal Chemistry. 31 (2): 187–94. PMID 25831025. doi:10.3109/14756366.2015.1021252. 
  2. ^ Manetti, D.; Ghelardini, C.; Bartolini, A.; Dei, S.; Galeotti, N.; Gualtieri, F.; Romanelli, M. N.; Teodori, E. (2000). "Molecular simplification of 1,4-diazabicyclo4.3.0nonan-9-ones gives piperazine derivatives that maintain high nootropic activity". Journal of medicinal chemistry. 43 (23): 4499–4507. PMID 11087574. doi:10.1021/jm000972h. 
  3. ^ Galeotti, N.; Ghelardini, C.; Pittaluga, A.; Pugliese, A.; Bartolini, A.; Manetti, D.; Romanelli, M.; Gualtieri, F. (2003). "AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)". Naunyn-Schmiedeberg's archives of pharmacology. 368 (6): 538–545. PMID 14600801. doi:10.1007/s00210-003-0812-6.